Oxford BioMedica PLC (OXB) - Net Assets
Based on the latest financial reports, Oxford BioMedica PLC (OXB) has net assets worth GBX32.73 Million GBX (≈ $3.98K USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX216.32 Million ≈ $26.32K USD) and total liabilities (GBX183.59 Million ≈ $22.34K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Oxford BioMedica PLC's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX32.73 Million |
| % of Total Assets | 15.13% |
| Annual Growth Rate | 15.15% |
| 5-Year Change | -46.35% |
| 10-Year Change | 455.23% |
| Growth Volatility | 110.83 |
Oxford BioMedica PLC - Net Assets Trend (1996–2024)
This chart illustrates how Oxford BioMedica PLC's net assets have evolved over time, based on quarterly financial data. Also explore OXB current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Oxford BioMedica PLC (1996–2024)
The table below shows the annual net assets of Oxford BioMedica PLC from 1996 to 2024. For live valuation and market cap data, see how much is Oxford BioMedica PLC worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | GBX60.49 Million ≈ $7.36K |
-22.29% |
| 2023-12-31 | GBX77.83 Million ≈ $9.47K |
-67.05% |
| 2022-12-31 | GBX236.19 Million ≈ $28.74K |
+26.08% |
| 2021-12-31 | GBX187.34 Million ≈ $22.79K |
+66.16% |
| 2020-12-31 | GBX112.75 Million ≈ $13.72K |
+49.08% |
| 2019-12-31 | GBX75.63 Million ≈ $9.20K |
+117.70% |
| 2018-12-31 | GBX34.74 Million ≈ $4.23K |
+465.26% |
| 2017-12-31 | GBX6.15 Million ≈ $747.79 |
-51.28% |
| 2016-12-31 | GBX12.62 Million ≈ $1.53K |
+15.80% |
| 2015-12-31 | GBX10.89 Million ≈ $1.33K |
-52.71% |
| 2014-12-31 | GBX23.04 Million ≈ $2.80K |
+158.92% |
| 2013-12-31 | GBX8.90 Million ≈ $1.08K |
-54.70% |
| 2012-12-31 | GBX19.64 Million ≈ $2.39K |
+10.53% |
| 2011-12-31 | GBX17.77 Million ≈ $2.16K |
+53.13% |
| 2010-12-31 | GBX11.61 Million ≈ $1.41K |
-44.67% |
| 2009-12-31 | GBX20.98 Million ≈ $2.55K |
-9.86% |
| 2008-12-31 | GBX23.27 Million ≈ $2.83K |
-27.12% |
| 2007-12-31 | GBX31.93 Million ≈ $3.89K |
+6.12% |
| 2006-12-31 | GBX30.09 Million ≈ $3.66K |
-35.43% |
| 2005-12-31 | GBX46.60 Million ≈ $5.67K |
+76.66% |
| 2004-12-31 | GBX26.38 Million ≈ $3.21K |
-25.09% |
| 2003-12-31 | GBX35.21 Million ≈ $4.28K |
+37.92% |
| 2002-12-31 | GBX25.53 Million ≈ $3.11K |
-31.93% |
| 2001-12-31 | GBX37.51 Million ≈ $4.56K |
+189.03% |
| 2000-12-31 | GBX12.98 Million ≈ $1.58K |
+241.41% |
| 1999-12-31 | GBX3.80 Million ≈ $462.47 |
-20.16% |
| 1998-12-31 | GBX4.76 Million ≈ $579.28 |
+72.44% |
| 1997-12-31 | GBX2.76 Million ≈ $335.93 |
+145.42% |
| 1996-12-31 | GBX1.12 Million ≈ $136.88 |
0.00% |
| 1996-09-30 | GBX1.12 Million ≈ $136.88 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Oxford BioMedica PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 39941500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX52.98 Million | 92.87% |
| Other Comprehensive Income | GBX8.71 Million | 15.27% |
| Other Components | GBX394.86 Million | 692.17% |
| Total Equity | GBX57.05 Million | 100.00% |
Oxford BioMedica PLC Competitors by Market Cap
The table below lists competitors of Oxford BioMedica PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Swift Networks Group Ltd
AU:SW1
|
$8.71 Million |
|
Bytes Technology Ltd
LSE:BYIT
|
$8.71 Million |
|
Sedania Innovator Bhd
KLSE:0178
|
$8.71 Million |
|
Grande Asset Hotels and Property Public Company Limited
BK:GRAND
|
$8.73 Million |
|
ASKOLL EVA S.P.A.
F:736
|
$8.71 Million |
|
Koszalinskie Przedsiebiorstwo Przemyslu Drzewnego SA
WAR:KPD
|
$8.71 Million |
|
Morien Resources Corp
V:MOX
|
$8.71 Million |
|
Intanwijaya Internasional Tbk
JK:INCI
|
$8.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oxford BioMedica PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 74,006,000 to 57,046,000, a change of -16,960,000 (-22.9%).
- Net loss of 43,190,000 reduced equity.
- New share issuances of 17,526,000 increased equity.
- Other comprehensive income increased equity by 10,521,000.
- Other factors decreased equity by 1,817,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-43.19 Million | -75.71% |
| Share Issuances | GBX17.53 Million | +30.72% |
| Other Comprehensive Income | GBX10.52 Million | +18.44% |
| Other Changes | GBX-1.82 Million | -3.19% |
| Total Change | GBX- | -22.92% |
Book Value vs Market Value Analysis
This analysis compares Oxford BioMedica PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1075.46x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 730.86x to 1075.46x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-09-30 | GBX0.81 | GBX593.00 | x |
| 1996-12-31 | GBX0.81 | GBX593.00 | x |
| 1997-12-31 | GBX1.46 | GBX593.00 | x |
| 1998-12-31 | GBX1.99 | GBX593.00 | x |
| 1999-12-31 | GBX1.23 | GBX593.00 | x |
| 2000-12-31 | GBX3.58 | GBX593.00 | x |
| 2001-12-31 | GBX7.65 | GBX593.00 | x |
| 2002-12-31 | GBX4.78 | GBX593.00 | x |
| 2003-12-31 | GBX6.09 | GBX593.00 | x |
| 2004-12-31 | GBX3.37 | GBX593.00 | x |
| 2005-12-31 | GBX5.80 | GBX593.00 | x |
| 2006-12-31 | GBX2.85 | GBX593.00 | x |
| 2007-12-31 | GBX2.87 | GBX593.00 | x |
| 2008-12-31 | GBX2.05 | GBX593.00 | x |
| 2009-12-31 | GBX1.84 | GBX593.00 | x |
| 2010-12-31 | GBX1.07 | GBX593.00 | x |
| 2011-12-31 | GBX0.95 | GBX593.00 | x |
| 2012-12-31 | GBX0.86 | GBX593.00 | x |
| 2013-12-31 | GBX0.31 | GBX593.00 | x |
| 2014-12-31 | GBX0.57 | GBX593.00 | x |
| 2015-12-31 | GBX0.21 | GBX593.00 | x |
| 2016-12-31 | GBX0.23 | GBX593.00 | x |
| 2017-12-31 | GBX0.10 | GBX593.00 | x |
| 2018-12-31 | GBX0.50 | GBX593.00 | x |
| 2019-12-31 | GBX1.04 | GBX593.00 | x |
| 2020-12-31 | GBX1.41 | GBX593.00 | x |
| 2021-12-31 | GBX2.19 | GBX593.00 | x |
| 2022-12-31 | GBX2.16 | GBX593.00 | x |
| 2023-12-31 | GBX0.77 | GBX593.00 | x |
| 2024-12-31 | GBX0.55 | GBX593.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oxford BioMedica PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -75.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -33.53%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 4.06x
- Recent ROE (-75.71%) is below the historical average (-56.29%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | -7.56% | 0.00% | 0.00x | 1.11x | GBX-197.50K |
| 1996 | -7.56% | 0.00% | 0.00x | 1.11x | GBX-197.50K |
| 1998 | -77.32% | -7362.00% | 0.01x | 1.10x | GBX-4.16 Million |
| 1999 | -110.21% | -960.78% | 0.09x | 1.21x | GBX-4.57 Million |
| 2000 | -38.55% | -683.33% | 0.05x | 1.10x | GBX-6.30 Million |
| 2001 | -22.37% | -2249.06% | 0.01x | 1.05x | GBX-12.14 Million |
| 2002 | -45.67% | -6739.88% | 0.01x | 1.05x | GBX-14.21 Million |
| 2003 | -30.49% | -2871.12% | 0.01x | 1.04x | GBX-14.26 Million |
| 2004 | -39.67% | -2084.46% | 0.02x | 1.08x | GBX-13.10 Million |
| 2005 | -19.50% | -1102.55% | 0.02x | 1.06x | GBX-13.74 Million |
| 2006 | -58.58% | -2319.21% | 0.02x | 1.18x | GBX-20.64 Million |
| 2007 | -47.88% | -211.79% | 0.12x | 1.92x | GBX-18.48 Million |
| 2008 | -43.15% | -54.59% | 0.43x | 1.85x | GBX-12.37 Million |
| 2009 | -16.76% | -18.38% | 0.44x | 2.10x | GBX-5.61 Million |
| 2010 | -88.67% | -92.26% | 0.43x | 2.21x | GBX-11.45 Million |
| 2011 | -71.08% | -163.66% | 0.30x | 1.47x | GBX-14.41 Million |
| 2012 | -44.44% | -112.56% | 0.32x | 1.24x | GBX-10.69 Million |
| 2013 | -124.70% | -206.44% | 0.39x | 1.53x | GBX-11.99 Million |
| 2014 | -37.59% | -63.60% | 0.40x | 1.47x | GBX-10.96 Million |
| 2015 | -119.51% | -81.83% | 0.31x | 4.76x | GBX-14.11 Million |
| 2016 | -131.91% | -59.91% | 0.49x | 4.51x | GBX-17.90 Million |
| 2017 | -146.71% | -23.99% | 0.57x | 10.64x | GBX-9.63 Million |
| 2018 | 21.71% | 11.29% | 0.59x | 3.24x | GBX4.07 Million |
| 2019 | -21.24% | -25.08% | 0.52x | 1.63x | GBX-23.63 Million |
| 2020 | -5.54% | -7.12% | 0.48x | 1.63x | GBX-17.52 Million |
| 2021 | 10.15% | 13.31% | 0.60x | 1.27x | GBX277.20K |
| 2022 | -19.13% | -27.97% | 0.30x | 2.25x | GBX-59.62 Million |
| 2023 | -212.81% | -175.89% | 0.35x | 3.41x | GBX-164.89 Million |
| 2024 | -75.71% | -33.53% | 0.56x | 4.06x | GBX-48.89 Million |
Industry Comparison
This section compares Oxford BioMedica PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $8,864,748
- Average return on equity (ROE) among peers: -251.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oxford BioMedica PLC (OXB) | GBX32.73 Million | -7.56% | 5.61x | $8.71 Million |
| 4BASEBIO UK SOCIETAS (4BB) | $7.12 Million | -72.33% | 0.64x | $951.45K |
| Aptamer Group PLC (APTA) | $245.81K | -274.50% | 4.65x | $205.09K |
| Arecor Therapeutics PLC (AREC) | $5.35 Million | -191.36% | 0.63x | $303.20K |
| Avacta Group PLC (AVCT) | $29.89 Million | -21.30% | 0.06x | $3.99 Million |
| BSF Enterprise Plc (BSFA) | $3.58 Million | -25.96% | 0.13x | $27.33K |
| Bioventix (BVXP) | $11.01 Million | 51.43% | 0.08x | $1.10 Million |
| Cizzle Biotechnology Holdings PLC (CIZ) | $32.00K | -956.25% | 1.81x | $127.81K |
| Amur Minerals Corporation (CRTX) | $20.48 Million | -8.91% | 0.04x | $80.26K |
| Fusion Antibodies PLC (FAB) | $50.13K | -935.06% | 5.06x | $193.60K |
| Faron Pharmaceuticals Oy (FARN) | $10.88 Million | -85.40% | 0.59x | $575.13K |
About Oxford BioMedica PLC
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The… Read more